Therefore, we further estimated the association between these mutations and the efficacy of immunotherapy in a published lung cancer dataset, and the results demonstrated that MUC19 and PCDHB5- mutations were related with favorable results of immunotherapy (Figure 4E) (24). Here, MUC19 is linked to lung carcinoma.